|
Getting your Trinity Audio player ready...
|
1. INTRODUCTION
According to a recent report by the World Health Organization (WHO), only 25% of the pharmaceutical products required by Nigerians are produced locally, while the remaining 75% are imported from countries such as India, the United Kingdom, and China. This imbalance underscores the underperformance of Nigeria’s local pharmaceutical manufacturing capacity. The country’s heavy reliance on imported pharmaceutical products exposes it to supply chain disruptions, foreign exchange volatility, drug shortages, and limited accessibility, all of which undermine public health and national industrial development.
As global markets evolve and healthcare demands intensify, Nigeria must prioritize modernizing its pharmaceutical sector through the adoption of innovative technologies that can catalyze local drug production. This article examines the existing legal and financial incentives available to pharmaceutical manufacturers in Nigeria and highlights critical regulatory and policy gaps that must be addressed to foster a sustainable, technology-driven pharmaceutical ecosystem.
2. OVERVIEW OF NIGERIA’S PHARMACEUTICAL INDUSTRY
Nigeria’s pharmaceutical industry comprises regulators, manufacturers, healthcare providers, non-governmental organizations, and international partners. Several laws govern the sector, from production and branding to distribution and sale. As technology continues to reshape the global pharmaceutical value chain, Nigeria’s regulatory framework is gradually evolving to accommodate digital and automated processes in drug production and distribution.
a. The National Agency for Food and Drug Administration and Control Act, 2004
Section 1 of the NAFDAC Act establishes the National Agency for Food and Drug Administration and Control (NAFDAC) as the primary regulatory authority for pharmaceutical products in Nigeria.
NAFDAC oversees the licensing of drug manufacturers, registration of pharmaceutical products, and inspection of facilities to ensure compliance with Good Manufacturing Practices (GMP). It also investigates violations and enforces sanctions against the production or distribution of substandard or counterfeit drugs. Related laws administered by the Agency include the Food and Drug Act Cap F.32 LFN, the Food, Drug and Related Products (Registration) Act Cap F.33, and the Counterfeit and Fake Drugs Unwholesome Processed Foods (Miscellaneous Provision) Act Cap. C.34 LFN 2004.
As technological advancement gains prominence in pharmaceutical production, they hold significant potential to streamline regulatory compliance with NAFDAC requirements, enabling real-time monitoring, digital batch record-keeping, and predictive quality assurance systems. However, NAFDAC has yet to issue formal guidelines on the application of technology within its regulatory framework, highlighting a critical gap and an urgent opportunity for targeted policy development.
b. Pharmacy Council of Nigeria (PCN) Act, 2022
The Pharmacy Council of Nigeria (PCN) Act establishes the Pharmacy Council of Nigeria, which serves as the statutory body regulating the practice and business of pharmacy in Nigeria. Its responsibilities include licensing pharmacists, pharmaceutical premises, and enforcing standards across the supply chain.
PCN plays a pivotal role in the oversight of local drug distribution channels, ensuring that medicines are handled by qualified professionals and that licensed premises meet operational standards. Sections 55 and 56 of the PCN Act empower the Council to seal non-compliant premises, impose penalties, and conduct compliance inspections. The Council has also issued guidelines, such as the 2021 Online Pharmacy Regulations, to provide regulatory clarity for online pharmacies and digital drug vendors.
For pharmaceutical manufacturers, especially those integrating innovative technology into warehouse management or automated distribution systems, PCN remains an essential interface as it sets the general standards to be met. The Pharmacists Council of Nigeria Online Pharmacy Regulations, 2020, contains several provisions that can reasonably be extended to regulate the adoption of innovative technology in pharmacy operations.
c. Federal Competition and Consumer Protection Commission (FCCPC) Act, 2018
The Federal Competition and Consumer Protection Commission (FCCPC) Act establishes the FCCPC, Nigeria’s primary authority for consumer protection and antitrust regulation. As innovative technology becomes increasingly integrated into drug marketing, pricing, and advertising on digital platforms, the FCCPC’s oversight will be essential to prevent price discrimination, anti-competitive practices, and the dissemination of misleading technology-driven content in pharmaceutical promotion.
d. Nigeria Data Protection Act, 2023
The Nigeria Data Protection Act (NDPA) and the General Application and Implementation Directive (GAID) are particularly relevant in regulating the use of innovative technologies in the pharmaceutical sector, as these technologies often involve the collection, processing, storage, transfer, and disposal of sensitive personal data, including patient health records, biometric identifiers, and treatment histories. The NDPA and GAID are administered by the Nigerian Data Protection Commission (NDPC), which registers and regulates data controllers and processors, enforces compliance, and investigates data breaches.
While the NDPA and GAID establish foundational data protection principles, there remains a need for sector-specific guidelines to govern the handling of sensitive health information. The NDPC and NAFDAC should therefore collaborate to develop regulatory sandboxes and ethical frameworks to guide the responsible use of innovative technologies in the pharmaceutical space.
Although these existing laws do not directly regulate the adoption of innovative technologies in Nigeria, they significantly influence their deployment, particularly in the areas of handling regulated products, processing personal data, and governing technology-driven medical decision tools or digital prescribing systems.
The most recent effort to establish a holistic framework for technological innovation is the National Artificial Intelligence Strategy (NAIS), released in 2024. This strategy serves as a comprehensive, multi-stakeholder roadmap for responsible technological advancement in Nigeria, emphasizing the development of specific legislation, closing infrastructural and knowledge gaps, and promoting ethical and inclusive participation across sectors. Nonetheless, there remains an urgent need for dedicated legislation to regulate the rapid adoption of innovative technologies, particularly within the health sector. The absence of such a framework creates legal uncertainty for both innovators and regulators, posing the risk of Nigeria falling behind global standards for responsible technology governance and inadvertently stifling innovation through regulatory ambiguity.
3. FINANCIAL AND INVESTMENT INCENTIVES LANDSCAPE
While the adoption of innovative technology holds significant potential to enhance pharmaceutical productivity, many businesses may struggle to implement it without structured financial support. The Nigerian government and private sector stakeholders can stimulate investment through the following incentives:
A. Existing Incentives: Currently, there are no dedicated incentives for the integration of innovative technology in Nigeria. As a result, businesses seeking to deploy such solutions must rely on their own resources. However, several existing incentives for local drug production, though not specifically designed for technology adoption, can be strategically leveraged to free up capital for investment in innovative technological solutions. These include the Pioneer Status Incentive, Import Duty Waivers, and the Central Bank of Nigeria’s Healthcare Sector Intervention Facility – Healthcare Sector Research and Development Intervention Scheme (HSRDIS).
B. Investments: Another viable option for businesses seeking funding to scale up local pharmaceutical production through innovative technology is investment from both local and foreign entities. Through Foreign Direct Investment (FDI), Foreign Portfolio Investment (FPI), grants, and individual or institutional funding, pharmaceutical companies can access the capital required to integrate innovative technological solutions into their operations.
Although several businesses explore this route, investors often remain cautious due to perceived risks. To de-risk local drug manufacturing and attract greater investment, key measures may include: establishing clear technology-specific regulations; introducing compliance frameworks that integrate innovative technologies; creating regulatory sandboxes for health tech and pharmaceutical innovation; strengthening intellectual property and data privacy protection; developing IP policies for technology-driven pharmaceutical assets and algorithms; providing tax credits for technology adoption and R&D; offering grants or subsidies for innovation; establishing dedicated pharmaceutical innovation hubs; and training key stakeholders, including regulators, pharmaceutical professionals, technology developers, and end users.
4. APPLICATIONS OF INNOVATIVE TECHNOLOGY IN THE PHARMACEUTICAL VALUE CHAIN
The integration of innovative technology into the pharmaceutical value chain offers transformative possibilities across the following key areas:
a. Drug Discovery and Development: Laboratory and clinical data can be leveraged through advanced analytical tools for predictive modeling, compound screening, and formulation optimization.
b. Manufacturing and Quality Control: Innovative technologies enable process automation, real-time monitoring, and the detection of defects or counterfeits during production to ensure that pharmaceutical products meet required industry standards.
c. Supply Chain and Inventory Management: Technology-driven systems can enhance demand forecasting, optimize logistics, and improve traceability of products throughout the supply chain.
d. Regulatory Compliance: Innovative tools can support document automation, pharmacovigilance, and real-time audits in line with the reporting requirements of NAFDAC and other regulatory bodies.
5. CONCLUSION
Innovative technology presents a transformative opportunity for Nigeria’s pharmaceutical sector. Realizing this potential, however, requires more than technological adoption; it demands robust legal and regulatory frameworks, targeted financial incentives, and strategic collaboration across the sector. With proactive policy implementation and visionary legal guidance, Nigeria can position itself not only to harness technology in pharmaceutical production but also to emerge as a continental leader in technology-driven drug development and manufacturing.
Francisca Igboanugo is the Team Lead in the Health and Pharmaceutical Sector at Stren & Blan Partners; Omolola Ambrose serves as the Deputy Team Lead, and Emmanuel Ughanze is an Associate of the team.
Stren & Blan Partners is a full-service commercial Law Firm that provides legal services to diverse local and multinational corporations. We have developed a clear vision for anticipating our clients’ business needs and surpassing their expectations, and we do this with an uncompromising commitment to client service and legal excellence. For more information, kindly contact: contact@strenandblan.com or call 0702 558 0053.
Connect with Stren & Blan Partners:
Website: www.strenandblan.com
LinkedIn: linkedin.com/company/strenandblan
Twitter: twitter.com/Strenandblan
Instagram: instagram.com/strenandblan
